Join our daily newsletter At The Bell to receive exclusive market insights
Control Bionics Ltd (ASX:CBL) has formalised two strategic partnerships representing its move into the U.S. sports performance market and the Japanese neurological rehabilitation market respectively, cutting deals with market leaders for both.
In the first case, CBL has acquired a 20% stake in Neuro Elite Athletics, the company responsible for NeuroBounce – a unique computerised electromyography (EMG)
training solution which enables an increase in vertical leap by five to 15 centimetres and enhances explosiveness in only eight sessions, with suitability for basketball, volleyball, and football athletes.
NeuroBounce uses CBL’s technology exclusively, and the latter’s investment – which represents $250,0000 – is intended to speed up the rollout of this program across U.S. markets. The projected revenues for NeuroBounce are also promising, coming in at US$25,000 annually for each program.
CBL has also entered a Memorandum of Understanding (MoU) with Stroke Lab, a Tokyo-based rehabilitation facility, to facilitate the localisation of its NeuroStrip technology for the Japanese market.
The MoU includes a framework for a joint operating agreement to be reached in the first quarter of 2025, which would boost CBL’s footprint in the Japanese rehab market, building on Stroke Lab’s extensive industry network.
NeuroStrip – launched in 2023 – is a wearable device that detects and amplifies muscle signals, and turns them into commands that allow users to control computers, smartphones, and other assistive technology.
The goal in both is to leverage this technology to boost improved sports performance, patient outcomes, and provide the platforms for expansion into other markets.
CBL has been trading at 6.5 cents through Monday morning.
Join the discussion: See what HotCopper users are saying about CBL and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
